食管癌手术后放疗的影响。
Impact of postoperative radiation after esophagectomy for esophageal cancer.
机构信息
Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA.
出版信息
J Thorac Oncol. 2010 Feb;5(2):244-50. doi: 10.1097/JTO.0b013e3181c5e34f.
INTRODUCTION
Though postoperative radiation for esophageal cancer is offered in selected cases, there is conflicting evidence as to whether it improves overall survival (OS). We performed a retrospective analysis using the Surveillance Epidemiology and End Results database to analyze the impact of adjuvant radiation in a large cohort of patients.
METHODS
From 1998 to 2005, patients diagnosed with stage T3-4N0M0 or T1-4N1M0 esophageal adenocarcinoma (AC) or squamous cell carcinoma (SCC) who were definitively treated with esophagectomy, with or without postoperative radiation, were selected. Kaplan-Meier and Cox regression analysis were used to compare OS and disease-specific survival (DSS).
RESULTS
A total of 1046 patients met the selection criteria: 683 (65.3%) received surgery alone and 363 (34.7%) received postoperative radiation. For American Joint Committee on Cancer stage III esophageal carcinoma (T3N1M0 or T4N0-1M0), there was significant improvement in median and 3-year OS (p < 0.001) and DSS (p < 0.001), respectively. This benefit was present for both SCC and AC. However, for American Joint Committee on Cancer stages IIA and IIB disease there was no significant differences in OS or DSS. Multivariate analysis revealed that postoperative radiation was the most significant predictor for improved OS (hazard ratio 0.70, 95% confidence interval 0.59-0.83, p < 0.001).
CONCLUSIONS
This large population-based review supports the use of postoperative radiation for stage III SCC and AC of the esophagus. Given the retrospective nature of this study, until appropriately powered randomized trials confirm these results, caution should be used before broadly applying these findings in clinical practice.
简介
尽管在某些情况下会为食管癌患者提供术后放疗,但关于其是否能提高总体生存率(OS),目前仍存在争议。我们使用监测、流行病学和最终结果(SEER)数据库进行了回顾性分析,以在大量患者队列中分析辅助放疗的影响。
方法
1998 年至 2005 年,选择经手术明确治疗且未接受术后放疗或接受术后放疗的 T3-4N0M0 或 T1-4N1M0 食管腺癌(AC)或鳞状细胞癌(SCC)患者。采用 Kaplan-Meier 和 Cox 回归分析比较 OS 和疾病特异性生存率(DSS)。
结果
共 1046 例患者符合入选标准:683 例(65.3%)仅接受手术治疗,363 例(34.7%)接受术后放疗。对于 AJCC 分期 III 期食管癌(T3N1M0 或 T4N0-1M0),中位 OS 和 3 年 OS 均有显著改善(p < 0.001),DSS 也有显著改善(p < 0.001)。SCC 和 AC 均有此获益。然而,对于 AJCC 分期 IIA 和 IIB 期疾病,OS 和 DSS 无显著差异。多因素分析显示,术后放疗是改善 OS 的最显著预测因素(风险比 0.70,95%置信区间 0.59-0.83,p < 0.001)。
结论
本大规模基于人群的回顾性研究支持对 III 期 SCC 和 AC 患者使用术后放疗。鉴于本研究的回顾性,在适当的大样本随机对照试验证实这些结果之前,在临床实践中广泛应用这些发现时应谨慎。